IP Library Granted Patent US 7,001,764
Granted Patent B2
US 7,001,764 · App. 10/139,089 · Granted Feb 21, 2006

Compositions comprising tissue specific adenoviral vectors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,001,764
App. No.
10/139,089
Granted
Feb 21, 2006
Kind
B2
Abstract

Compositions comprising host cell specific adenovirus vehicles are provided for transfecting target host cells. The compositions comprise replication competent adenovirus having an adenovirus gene essential for replication under transcriptional control of a cell type specific transcriptional response element (TRE) and polyethylene glycol (PEG) as a masking agent.

Claims (23)

1. A composition comprising:

a replication competent adenovirus having an adenovirus gene essential for replication under transcriptional control of a cell type specific transcriptional response element (TRE); and

a masking agent, wherein the masking agent is polyethylene glycol (PEG).

2. The composition according to claim 1 , wherein said adenovirus gene is an early gene.

3. The composition according to claim 2 , wherein said early gene is selected from the group consisting of E1A, E1B and E4.

4. The composition according to claim 1 , wherein said adenovirus further comprises a transgene.

5. The composition according to claim 1 , wherein said cell type specific TRE is prostate cell specific.

6. The composition according to claim 5 , wherein said adenovirus is replication competent only in mammalian cells expressing prostate specific antigen.

7. The composition according to claim 5 , wherein said cell type specific TRE comprises nucleotides −540 to +8 relative to the transcription start site of the prostate specific antigen gene.

8. The composition according to claim 5 , wherein said prostate cell specific response element comprises the enhancer sequence in the region −5322 to −3739 relative to the transcription start site of the prostate specific antigen gene.

9. The composition according to claim 5 , wherein said prostate cell specific response element is a probasin TRE.

10. The composition according to claim 5 , wherein said prostate cell specific response element is a hKLK2-TRE.

11. The composition according to claim 1 , wherein said adenovirus gene essential for replication is under transcriptional control of an α-fetoprotein transcriptional regulatory element (AFP-TRE).

12. The composition according to claim 1 , wherein said adenovirus gene essential for replication is under transcriptional control of a MUC1-TRE.

13. The composition according to claim 1 , wherein said adenovirus gene essential for replication is under transcriptional control of a CEA-TRE.

14. The composition according to claim 1 , further comprising a physiologically acceptable carrier.

15. The composition according to claim 1 , wherein said PEG is of a molecular weight between about 2500 to about 30,000 Da.

16. The composition according to claim 15 , wherein said PEG is of a molecular weight between about 3000 to about 20,000 Da.

17. The composition of claim 16 , wherein said PEG is of a molecular weight between about 5000 to about 10,000 Da.

18. The composition according to claim 1 , wherein said PEG is covalently attached to said adenovirus.

19. The composition according to claim 18 , wherein the PEG is covalently attached to the adenovirus by using N-hydroxysuccinimidyl (NHS) active ester.

20. The composition according to claim 19 , wherein said N-hydroxysuccinimidyl (NHS) active ester is selected from the group consisting of succinimidyl succinate, succinimidyl succinamide, and succinimidyl propionate.

21. The composition according to claim 20 , wherein said N-hydroxysuccinimidyl (NHS) active ester is succinimidyl succinate.

Assignments (4)
CHANGE OF NAME Recorded Nov 9, 2020
From: COLD GENESYS, INC.
To: CG ONCOLOGY, INC.
Reel/Frame 054362/0411 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2010
From: BIOSANTE PHARMACEUTICALS, INC.
To: COLD GENESYS, INC.
Reel/Frame 025550/0722 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2010
From: CELL GENESYS, INC.
To: BIOSANTE PHARMACEUTICALS, INC.
Reel/Frame 023973/0005 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2002
From: LITTLE, ANDREW S.; LAMPARSKI, HENRY G.; HENDERSON, DANIEL R.; SCHUUR, ERIC R.
To: CELL GENESYS, INC.
Reel/Frame 013294/0851 →